Phase II failure for CombinatoRx therapy

CombinatoRx of Cambridge, MA announced that a Phase II trial of CRx-150 failed to meet its primary endpoint as a therapy for periodontitis. The mid-stage trial did not demonstrate a reduction in a key indicator of inflammation among patients suffering from the bacterial gum disease. Looking for signs that the therapy reduced inflammatory biomarkers in patients, researchers failed to see an improvement in C-reactive protein after 42 days of treatment. The trial did hit a secondary endpoint in reducing CRP during the acute inflammatory stage of the disease. CombinatoRx plans further trials to better understand how the therapy works.

- here's the release on the trial data